Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Asset Writedowns and Impairment (2020 - 2025)

PROCEPT BioRobotics has reported Asset Writedowns and Impairment over the past 6 years, most recently at -$861000.0 for Q4 2025.

  • Quarterly results put Asset Writedowns and Impairment at -$861000.0 for Q4 2025, down 243.5% from a year ago — trailing twelve months through Dec 2025 was $565000.0 (down 69.96% YoY), and the annual figure for FY2025 was $565000.0, down 69.96%.
  • Asset Writedowns and Impairment for Q4 2025 was -$861000.0 at PROCEPT BioRobotics, down from $526000.0 in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for PRCT hit a ceiling of $1.3 million in Q3 2024 and a floor of -$995000.0 in Q4 2023.
  • Median Asset Writedowns and Impairment over the past 5 years was $228000.0 (2023), compared with a mean of $201615.4.
  • Peak annual rise in Asset Writedowns and Impairment hit 567.82% in 2023, while the deepest fall reached 3880.0% in 2023.
  • PROCEPT BioRobotics' Asset Writedowns and Impairment stood at $113000.0 in 2021, then tumbled by 122.12% to -$25000.0 in 2022, then crashed by 3880.0% to -$995000.0 in 2023, then soared by 160.3% to $600000.0 in 2024, then plummeted by 243.5% to -$861000.0 in 2025.
  • The last three reported values for Asset Writedowns and Impairment were -$861000.0 (Q4 2025), $526000.0 (Q3 2025), and $600000.0 (Q2 2025) per Business Quant data.